After receiving three ketamine therapy sessions in Awakn’s Phase 2 trial, patients with alcohol use disorder achieved an increase in abstinence from around 2% to 86%. This means they abstained from alcohol for an average of 162 of the 180 days following the treatment đź‘Ź
The results were so encouraging that the UK government granted the company CA$2.5M to fund Phase 3 of the trial.
The grant covers two-thirds of Awakn’s costs and marks the first time that a Phase 3 psychedelics trial has received government funding.
With 280 patients across 7 sites in the UK, it will be the largest ketamine-assisted therapy trial to date!